CABA

Mizuho Securities analyst Vamil Divan maintained a Buy rating on Cabaletta Bio (CABA – Research Report) today and set a price target of $20.00. The company's shares closed last Thursday at $1.32, close to its 52-week low of $1.20. According to TipRanks.com, Divan is a 1-star analyst with an average return of -2.2% and a 45.7% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals. Currently, the analyst consensus on Cabaletta Bio is a Strong Buy with an average price target of $15.33. See today’s best-performing stocks on TipRanks >> Cabaletta Bio's market cap is currently $35.
https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-its-buy-rating-for-cabaletta-bio-caba?utm_source=advfn.com&utm_medium=referral